Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acinetobacter baumannii surface antigens represent a broad category of molecules located on the exterior of this Gram-negative opportunistic pathogen, including outer membrane proteins (OMPs), lipopolysaccharides (LPS), and capsular polysaccharides (Kim et al., 2021, Frontiers in Cellular and Infection Microbiology). These antigens are essential for the bacterium's survival and pathogenicity, mediating critical processes such as adhesion to host cells, biofilm development, and the acquisition of essential nutrients like iron through siderophore receptors (Singh et al., 2022, Expert Review of Vaccines). In clinical settings, these surface components are major virulence factors that allow the organism to resist desiccation, evade the host immune system, and survive in the presence of many traditional antibiotics. Consequently, they have become high-priority targets for the development of novel therapeutic interventions, particularly against carbapenem-resistant strains. Current pharmacological approaches include the use of small molecules like zosurabalpin, which inhibits the LptB2FGC complex responsible for transporting LPS to the cell surface (Pahil et al., 2024, Nature), as well as experimental monoclonal antibodies and vaccines designed to neutralize specific OMPs like OmpA or BauA. Targeting these surface-exposed structures aims to disrupt the structural integrity of the pathogen or enhance its recognition and clearance by the host's immune system.
Inhibition of the LptB2FGC complex to block lipopolysaccharide transport to the outer membrane; Opsonization and neutralization of virulence factors; Induction of protective immune responses.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acinetobacter baumannii surface antigens.